ProfileGDS5678 / 1420671_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 92% 91% 89% 96% 93% 91% 88% 89% 93% 81% 82% 88% 83% 83% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.4765292
GSM967853U87-EV human glioblastoma xenograft - Control 27.4753891
GSM967854U87-EV human glioblastoma xenograft - Control 37.1506189
GSM967855U87-EV human glioblastoma xenograft - Control 49.0655996
GSM967856U87-EV human glioblastoma xenograft - Control 58.0639893
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.2516391
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.6013288
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.0169889
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.8511993
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.9046181
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.8896482
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.828988
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.107983
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.0802783